<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27034" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pernicious Anemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vaqar</surname>
            <given-names>Sarosh</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shackelford</surname>
            <given-names>Karen B.</given-names>
          </name>
          <aff>University of Mississippi School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarosh Vaqar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karen Shackelford declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27034.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Pernicious anemia is a relatively rare autoimmune disorder that causes diminishment in dietary vitamin B12 absorption, resulting in B12 deficiency and subsequent megaloblastic anemia. It affects people of all ages worldwide, particularly those over 60. Despite the advances in understanding, making the diagnosis can be challenging for clinicians due to its complexity, broad spectrum of clinical presentation, and limitations of the currently available diagnostic tests. Once diagnosed, prompt treatment with B12 supplementation commonly reverses the patient's anemia; however, they will require lifelong supplementation and monitoring. This activity reviews the etiology, evaluation, and treatment of pernicious anemia and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of pernicious anemia.</p></list-item><list-item><p>Select diagnostic testing based on clinical evidence.</p></list-item><list-item><p>Implement the guideline-recommended treatment for patients with pernicious anemia.</p></list-item><list-item><p>Explain the roles of an interprofessional team in the evaluation and management of patients with suspected pernicious anemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27034&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27034">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27034.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pernicious anemia is a relatively rare autoimmune disorder that causes diminishment in dietary vitamin B12 (cobalamin) absorption, resulting in B12 deficiency and subsequent megaloblastic anemia. It affects people of all ages worldwide, particularly those over 60. Despite the advances in understanding, making the diagnosis can be challenging for clinicians due to its complexity, broad spectrum of clinical presentation, and limitations of the currently available diagnostic tests. Once diagnosed, prompt treatment with B12 supplementation&#x000a0;commonly reverses the patient's anemia; however, they will require lifelong supplementation and monitoring.</p>
      </sec>
      <sec id="article-27034.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Pernicious anemia is a complex disease, with a clear autoimmune basis. The anemia is&#x000a0;megaloblastic and is caused by vitamin B12 deficiency secondary to intrinsic factor (IF) deficiency.<xref ref-type="bibr" rid="article-27034.r1">[1]</xref>&#x000a0;IF is a glycoprotein produced and secreted by parietal cells that binds B12 and facilitates its transport to the terminal ileum for absorption.&#x000a0;Anti-IF antibodies inhibit B12 from binding to IF, preventing B12/IF complex formation or binding to the B12/IF complex, preventing intestinal absorption.</p>
        <p>Pernicious anemia is found in up to 25% of patients with autoimmune gastritis (AIG), which affects the corpus and fundus, spares the antrum, and is characterized by antiparietal cell antibodies destroying parietal cells located only in the oxyntic mucosa, which produce IF and hydrochloric acid. In turn, achlorhydria causes a decrease in the release of cobalamin bound to dietary protein, and fewer parietal cells are available to produce the IF needed for dietary B12 absorption. The term pernicious anemia has been used at times as a synonym for AIG; however, it is considered a late-stage manifestation as a part of the AIG clinical spectrum.<xref ref-type="bibr" rid="article-27034.r2">[2]</xref><xref ref-type="bibr" rid="article-27034.r3">[3]</xref><xref ref-type="bibr" rid="article-27034.r4">[4]</xref></p>
        <p>Patients with pernicious anemia also have a higher incidence of co-occurring autoimmune disorders, including diabetes mellitus type 1, autoimmune thyroid disease, and vitiligo.<xref ref-type="bibr" rid="article-27034.r1">[1]</xref><xref ref-type="bibr" rid="article-27034.r5">[5]</xref><xref ref-type="bibr" rid="article-27034.r6">[6]</xref><xref ref-type="bibr" rid="article-27034.r7">[7]</xref>&#x000a0;Furthermore,&#x000a0;5 genome-wide significant signals for pernicious anemia have been identified, providing evidence for genetic risk factors.<xref ref-type="bibr" rid="article-27034.r8">[8]</xref></p>
        <p>Whether or not Helicobacter pylori plays a causative role in pernicious anemia is unclear.<xref ref-type="bibr" rid="article-27034.r9">[9]</xref></p>
      </sec>
      <sec id="article-27034.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Pernicious anemia is a relatively rare condition, with a prevalence of less than 1% in populations of European ancestry. Worldwide, pernicious anemia is a common cause of megaloblastic anemia; it affects people of all ages, particularly those over 60-70 (~2% prevalence); it affects both sexes with a varying geographical female-to-male ratio; and the prevalence is lower in those of Asian descent compared to other studied populations.<xref ref-type="bibr" rid="article-27034.r10">[10]</xref><xref ref-type="bibr" rid="article-27034.r11">[11]</xref><xref ref-type="bibr" rid="article-27034.r12">[12]</xref></p>
      </sec>
      <sec id="article-27034.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The primary pathophysiological mechanism in pernicious anemia is diminished dietary B12 absorption due to IF deficiency. Vitamin B12 is found in meat, eggs, and dairy products and is essential for erythropoiesis and nerve myelination; therefore, its deficiency can lead to megaloblastic anemia due to disrupted DNA synthesis and demyelinated nerves. B12 deficiency causes megaloblastic changes in all formed blood elements, but erythrocytes show the most significant changes, with the degree of anemia corresponding to the severity of red blood cell morphologic changes.<xref ref-type="bibr" rid="article-27034.r13">[13]</xref></p>
        <p>Dietary B12 is released from food carrier proteins via proteolysis in the acidic gastric environment and binds to haptocorrin, protecting B12 from degradation.<xref ref-type="bibr" rid="article-27034.r14">[14]</xref>&#x000a0;B12 is released from haptocorrin in the small intestine by pancreatic proteases and binds to IF produced by gastric parietal cells. The IF-B12 complex binds to cubam receptors in the terminal ileum, is endocytosed, binds to transcobalamin, then is released in the bloodstream and delivered to transcobalamin cell receptors. After cellular uptake and intracellular release, B12 is converted to adenosylcobalamin and methylcobalamin, where they serve as cofactors for the two B12-dependent enzymatic reactions.<xref ref-type="bibr" rid="article-27034.r15">[15]</xref></p>
        <p>Vitamin B12 deficiency prevents the proper functioning of these coenzymes, leading to an accumulation of their substrate in plasma. Specifically, adenosylcobalamin deficiency results in an accumulation of methylmalonic acid (MMA), and methylcobalamin deficiency in an accumulation of homocysteine. Additionally, the formation of S-adenosylmethionine (SAM) and methionine diminish.<xref ref-type="bibr" rid="article-27034.r16">[16]</xref><xref ref-type="bibr" rid="article-27034.r17">[17]</xref></p>
        <p>SAM is the methyl donor to key substrates, such as nucleic acids, proteins, phospholipids, and neurotransmitters. As a donor in DNA methylation, it plays an important role in epigenetic adaptability to developmental and environmental factors.<xref ref-type="bibr" rid="article-27034.r18">[18]</xref>&#x000a0;Homocysteine excess can cause cellular stress, apoptosis, and homocysteinylation-induced structural and functional alterations in proteins.<xref ref-type="bibr" rid="article-27034.r19">[19]</xref>&#x000a0;Moreover, elevated plasma total homocysteine is associated with white matter damage, neurofibrillary tangles, brain atrophy, cognitive decline, and dementia.<xref ref-type="bibr" rid="article-27034.r20">[20]</xref>&#x000a0;The effects of accumulated MMA are unclear.<xref ref-type="bibr" rid="article-27034.r16">[16]</xref></p>
      </sec>
      <sec id="article-27034.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Pernicious anemia develops slowly, with a progression time to apparent clinical B12 deficiency of&#x000a0;2 to&#x000a0;5 years.<xref ref-type="bibr" rid="article-27034.r21">[21]</xref> Symptoms may not manifest until the anemia is relatively profound because compensatory cardiopulmonary mechanisms facilitate increases in oxygen delivery. Due to its insidious nature and the wide array of potential presenting symptoms, a high index of clinical suspicion is often necessary for the judicious&#x000a0;use of appropriate testing to make a prompt diagnosis. Patients may present with constitutional, neurological, psychiatric, otolaryngologic, cardiopulmonary,&#x000a0;and/or gastrointestinal&#x000a0;symptoms, which are often present in other conditions, resulting in a missed or delayed diagnosis.<xref ref-type="bibr" rid="article-27034.r1">[1]</xref><xref ref-type="bibr" rid="article-27034.r22">[22]</xref><xref ref-type="bibr" rid="article-27034.r23">[23]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Constitutional: fatigue, lethargy, anorexia, weight loss</p>
          </list-item>
          <list-item>
            <p>Neurological: headache, confusion, difficulty concentrating, memory loss, cognitive decline, paraesthesias, numbness, imbalance</p>
          </list-item>
          <list-item>
            <p>Psychiatric: emotional lability, depression, personality changes, psychosis</p>
          </list-item>
          <list-item>
            <p>Otolaryngologic:&#x000a0;hypogeusia/ageusia, glossitis</p>
          </list-item>
          <list-item>
            <p>Cardiopulmonary: palpitations, dyspnea</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal: dyspepsia, diarrhea, decreased appetite</p>
          </list-item>
        </list>
        <p>The physical examination may be notable for pallor, dry skin, jaundice, glossitis (tender, smooth, red tongue), and tachycardia.&#x000a0;In patients of European ancestry, &#x0201c;the melding of severe pallor with jaundice caused by hemolysis produces a peculiar lemon-yellow skin color.&#x0201d;<xref ref-type="bibr" rid="article-27034.r13">[13]</xref>&#x000a0;</p>
        <p>Peripheral neuropathy is an early neurological manifestation, which may be followed by subacute combined degeneration (SCD) of the spinal cord in later stages. It&#x000a0;is typically symmetric and affects the legs more than the arms. Examination shows a decrease in sensitivity to light touch, pinprick, and vibration. Patients with severe loss of position sense may demonstrate a positive Romberg test. Deep tendon ankle reflexes are commonly hypoactive or absent, while more proximal reflexes may still be intact. Importantly, neurologic findings may be present in the absence of anemia. Examination of a patient with SCD will likely demonstrate limb weakness and ataxia, and they may report visual disturbances. The prompt recognition of SCD is important because early diagnosis and treatment improve the chances of recovery.<xref ref-type="bibr" rid="article-27034.r24">[24]</xref></p>
        <p>A neuropsychiatric evaluation may be required.<xref ref-type="bibr" rid="article-27034.r25">[25]</xref>&#x000a0;Additionally, the clinician should inquire whether the patient, a parent, or a sibling has diabetes mellitus type 1, vitiligo, or hypothyroidism because a positive personal or family history of an autoimmune condition increases the pretest probability of pernicious anemia.<xref ref-type="bibr" rid="article-27034.r26">[26]</xref></p>
      </sec>
      <sec id="article-27034.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Making a definitive diagnosis of pernicious anemia can be &#x0201c;problematic&#x0201d; due to the Schilling test becoming obsolete and the absence of a currently approved B12 absorption test.<xref ref-type="bibr" rid="article-27034.r13">[13]</xref>&#x000a0;Furthermore, there are multiple diagnostic algorithms and varying diagnostic criteria.<xref ref-type="bibr" rid="article-27034.r1">[1]</xref><xref ref-type="bibr" rid="article-27034.r22">[22]</xref><xref ref-type="bibr" rid="article-27034.r23">[23]</xref><xref ref-type="bibr" rid="article-27034.r27">[27]</xref><xref ref-type="bibr" rid="article-27034.r28">[28]</xref><xref ref-type="bibr" rid="article-27034.r29">[29]</xref>&#x000a0;Evaluation will likely include a combination of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial serology: complete blood count (CBC), cobalamin level, folate level, iron panel (serum iron, total iron-binding capacity, ferritin), reticulocyte count</p>
          </list-item>
          <list-item>
            <p>Peripheral blood smear</p>
          </list-item>
          <list-item>
            <p>Follow-up serology: anti-IF antibodies, antiparietal cell antibodies</p>
          </list-item>
          <list-item>
            <p>Additional serology: MMA, fasting homocysteine, holotranscobalamin (HTC)</p>
          </list-item>
          <list-item>
            <p>Bone marrow biopsy</p>
          </list-item>
          <list-item>
            <p>Endoscopy with biopsies</p>
          </list-item>
        </list>
        <p>A CBC may be significant for anemia, macrocytosis (mean corpuscular volume &#x02265;100 fl), and pancytopenia (due to ineffective erythropoiesis and myelopoiesis). However, about one-third of patients with B12 deficiency may not have macrocytosis.<xref ref-type="bibr" rid="article-27034.r1">[1]</xref><xref ref-type="bibr" rid="article-27034.r22">[22]</xref>&#x000a0;Normocytic anemia can be seen if there is concomitant iron deficiency anemia, a complication of achlorhydria, or another condition causing microcytosis that can mask the macrocytosis. Iron deficiency may precede a pernicious anemia diagnosis or be concomitant with it.<xref ref-type="bibr" rid="article-27034.r1">[1]</xref><xref ref-type="bibr" rid="article-27034.r28">[28]</xref>&#x000a0;Moreover, pernicious anemia can present with nonanemic macrocytosis months before the diagnosis and neurologic signs and symptoms can occur in the absence of anemia or macrocytosis in 25 to 30% of&#x000a0;patients eventually diagnosed with pernicious anemia.<xref ref-type="bibr" rid="article-27034.r1">[1]</xref><xref ref-type="bibr" rid="article-27034.r29">[29]</xref>&#x000a0;A reticulocyte count may show a reduction in the absolute number of reticulocytes.</p>
        <p>A peripheral blood smear may show macro-ovalocytes, hypersegmented neutrophils, and anisopoikilocytosis. Although hypersegmented neutrophils are often considered a hallmark of megaloblastic anemia, they are not specific, as they can be seen in other types of anemia, like iron deficiency anemia. Hypersegmented neutrophils typically precede macrocytosis and anemia; however, in advanced disease, they may be rare or absent.</p>
        <p>An isolated serum cobalamin level has poor sensitivity and specificity for reliably detecting B12 deficiency.<xref ref-type="bibr" rid="article-27034.r13">[13]</xref>&#x000a0;B12 deficiency is defined by&#x000a0;a serum cobalamin level of &#x0003c;200 ng/L in the appropriate clinical context. Patients with pernicious anemia and serum cobalamin levels &#x02265;200 ng/L may have true B12 deficiency because levels can be falsely elevated in up to 35% of these patients.<xref ref-type="bibr" rid="article-27034.r1">[1]</xref>&#x000a0;In 2018, authors reviewing evidence on &#x0201c;methods to assess B12 bioavailability and technologies to enhance its absorption&#x0201d; concluded that &#x0201c;in most cases, the evidence of absorption enhancement is limited.&#x0201d;<xref ref-type="bibr" rid="article-27034.r30">[30]</xref>&#x000a0;The CobaSorb test has shown promise, but it does not discriminate between gastric and intestinal causes of B12 malabsorption, and it cannot be used once a patient is treated with B12.<xref ref-type="bibr" rid="article-27034.r31">[31]</xref><xref ref-type="bibr" rid="article-27034.r32">[32]</xref></p>
        <p>In patients with serum cobalamin levels &#x02265;200 ng/L diagnostic performance may be enhanced by measuring serum MMA, fasting homocysteine, and HTC.<xref ref-type="bibr" rid="article-27034.r1">[1]</xref>&#x000a0;Elevated MMA and/or fasting homocysteine are indicators of B12 deficiency in patients without evidence of impaired renal function or an inherited cobalamin processing enzyme defect. MMA is more sensitive and more specific, and elevation is seen only in patients with B12 deficiency. Homocysteine levels may also increase in folate deficiency, pyridoxine deficiency, and hypothyroidism. Serum HTC levels may be used for assessing B12 status, with or without MMA and/or homocysteine, and may reflect B12 absorptive capacity.<xref ref-type="bibr" rid="article-27034.r13">[13]</xref></p>
        <p>Folate levels should be determined to exclude macrocytic anemia secondary to folate deficiency and because treating B12-deficient patients with folate alone may worsen associated neurologic damage.<xref ref-type="bibr" rid="article-27034.r23">[23]</xref> Iron deficiency anemia is present in up to 50% of patients with AIG, and pernicious anemia is present in up to 25% of patients with AIG<xref ref-type="bibr" rid="article-27034.r2">[2]</xref>; therefore, an iron panel is indicated in patients diagnosed with pernicious anemia.</p>
        <p>Follow-up serology will include anti-IF antibodies with or without antiparietal cell antibodies. Anti-IF antibodies are 40 to 60% sensitive in detecting pernicious anemia, with the rate of positivity rising with disease progression. The specificity of anti-IF antibody testing is almost&#x000a0;100%.&#x000a0;Although antiparietal cell antibodies are present in 90% of patients with pernicious anemia, they are less specific than anti-IF antibodies. Notably combining the two has been shown to significantly increase their diagnostic performance for pernicious anemia (73% sensitivity and 100% specificity).<xref ref-type="bibr" rid="article-27034.r28">[28]</xref><xref ref-type="bibr" rid="article-27034.r33">[33]</xref></p>
        <p>A serum cobalamin of &#x0003c;200 ng/L plus the presence of anti-IF antibodies confirms a diagnosis of pernicious anemia.</p>
        <p>According to the British Committee for Standards in Hematology, all patients with anemia, neuropathy, or glossitis, and suspected of having pernicious anemia, should be tested for anti-IF antibodies regardless of cobalamin levels. Secondly, the committee recommends anti-IF antibody testing in patients found to have a low serum cobalamin level in the absence of anemia and who do not have food malabsorption or other causes of deficiency to clarify whether they have an early or latent presentation of pernicious anemia.&#x000a0;Thirdly, antiparietal cell antibody testing for diagnosing pernicious anemia is not recommended.<xref ref-type="bibr" rid="article-27034.r26">[26]</xref></p>
        <p>Of note, there are two types of IF autoantibodies: type 1 are &#x0201c;blocking autoantibodies&#x0201d; that inhibit B12 from binding to IF, preventing B12/IF complex formation, and type 2 are &#x0201c;binding autoantibodies&#x0201d; that bind to the B12/IF complex, preventing intestinal absorption. Type 1 is used in evaluating suspected pernicious anemia because&#x000a0;it is highly specific and is the type present in approximately 70% of patients.<xref ref-type="bibr" rid="article-27034.r13">[13]</xref><xref ref-type="bibr" rid="article-27034.r29">[29]</xref></p>
        <p>Histological examination after a bone marrow biopsy is usually unnecessary. When performed, it will show hypercellularity with a shift toward immaturity, including abnormal maturation of myeloid and erythroid cell lines.<xref ref-type="bibr" rid="article-27034.r1">[1]</xref><xref ref-type="bibr" rid="article-27034.r23">[23]</xref></p>
        <p>As mentioned earlier, pernicious anemia is found in up to 25% of patients with AIG as a late-stage manifestation. Because autoimmune chronic atrophic gastritis is characterized by an elevated fasting serum gastrin level, the fasting serum gastrin assay can play a role in establishing a pernicious anemia diagnosis in difficult cases.<xref ref-type="bibr" rid="article-27034.r27">[27]</xref><xref ref-type="bibr" rid="article-27034.r28">[28]</xref>&#x000a0;Moreover, a deficiency in gastric intrinsic factor output after pentagastrin stimulation is specific for the diagnosis of pernicious anemia and can be used when evaluating serological markers in certain patients.<xref ref-type="bibr" rid="article-27034.r34">[34]</xref></p>
        <p>According to a 2021 American Gastroenterological Association clinical practice update, patients with a new pernicious anemia diagnosis who have not had a recent endoscopy should undergo endoscopy with topographical biopsies to confirm corpus-predominant atrophic gastritis for risk stratification and to rule out prevalent gastric neoplasia, including neuroendocrine tumors.<xref ref-type="bibr" rid="article-27034.r3">[3]</xref></p>
      </sec>
      <sec id="article-27034.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Lifelong treatment for patients with confirmed pernicious anemia starts with an intramuscular (IM) injection of 1000 micrograms of B12 (hydroxocobalamin in Europe or cyanocobalamin in the United States) administered daily or every other day for&#x000a0;1 to&#x000a0;2 weeks, followed by weekly injections for&#x000a0;1 to&#x000a0;2 months, then a monthly injection (cyanocobalamin) or every&#x000a0;2 to&#x000a0;3 months (hydroxocobalamin).<xref ref-type="bibr" rid="article-27034.r11">[11]</xref><xref ref-type="bibr" rid="article-27034.r16">[16]</xref><xref ref-type="bibr" rid="article-27034.r21">[21]</xref><xref ref-type="bibr" rid="article-27034.r26">[26]</xref></p>
        <p>Following the initial intensive treatment phase, patients can continue IM injections, or they can be offered high-dose oral B12 supplementation for the lifelong maintenance phase. In a 2016 review of oral B12 replacement for treating pernicious anemia, the authors concluded that "oral vitamin B12 is an effective alternative to vitamin B12 IM injections."<xref ref-type="bibr" rid="article-27034.r35">[35]</xref>&#x000a0;High-dose cyanocobalamin (1000&#x02013;2000 micrograms) is most commonly taken daily as an oral tablet.&#x000a0;Alternate formulations include sublingual and intranasal, but they are not routinely recommended.<xref ref-type="bibr" rid="article-27034.r11">[11]</xref><xref ref-type="bibr" rid="article-27034.r16">[16]</xref><xref ref-type="bibr" rid="article-27034.r21">[21]</xref><xref ref-type="bibr" rid="article-27034.r26">[26]</xref></p>
      </sec>
      <sec id="article-27034.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>
<bold>Other causes of megaloblastic anemia:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>myelodysplastic syndromes</p>
          </list-item>
          <list-item>
            <p>hemolytic anemia</p>
          </list-item>
          <list-item>
            <p>thrombotic thrombocytopenic purpura</p>
          </list-item>
        </list>
        <p>
<bold>Other causes of B12 deficiency:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>food-cobalamin malabsorption</p>
          </list-item>
          <list-item>
            <p>veganism</p>
          </list-item>
          <list-item>
            <p>metformin</p>
          </list-item>
          <list-item>
            <p>long-term proton pump inhibitor therapy</p>
          </list-item>
          <list-item>
            <p>estrogen contraceptive pills</p>
          </list-item>
          <list-item>
            <p>gastric surgery</p>
          </list-item>
          <list-item>
            <p>ileal disease</p>
          </list-item>
          <list-item>
            <p>ileal resection</p>
          </list-item>
        </list>
        <p>
<bold>Other causes of macrocytosis:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>folate deficiency</p>
          </list-item>
          <list-item>
            <p>methotrexate</p>
          </list-item>
          <list-item>
            <p>alcohol use disorder</p>
          </list-item>
        </list>
        <p>
<bold>Other causes of peripheral neuropathy:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>diabetes mellitus</p>
          </list-item>
          <list-item>
            <p>carpal tunnel syndrome</p>
          </list-item>
          <list-item>
            <p>infections</p>
          </list-item>
          <list-item>
            <p>medications</p>
          </list-item>
          <list-item>
            <p>other vitamin deficiencies</p>
          </list-item>
          <list-item>
            <p>alcohol use disorder</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27034.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Before the discovery of treatment, pernicious anemia could be fatal.<xref ref-type="bibr" rid="article-27034.r13">[13]</xref>&#x000a0;The prognosis since has been excellent with appropriate management, except for patients diagnosed with SCD. Although B12&#x000a0;supplementation&#x000a0;stops progression and improves neurologic deficits in most patients with SCD, evidence shows complete resolution only occurs in a small percentage of them.<xref ref-type="bibr" rid="article-27034.r24">[24]</xref>&#x000a0;After treatment initiation for pernicious anemia, reticulocytosis&#x000a0;begins&#x000a0;approximately 5 days later, followed by red blood cell count normalization within&#x000a0;4 to&#x000a0;6 weeks.<xref ref-type="bibr" rid="article-27034.r11">[11]</xref>&#x000a0;Typically, neurological symptom improvement is slower than hematological improvement, and the&#x000a0;degree of neurological recovery is&#x000a0;inversely proportional to the severity and duration&#x000a0;of&#x000a0;symptoms before treatment. Psychiatric symptoms such as emotional lability and psychosis may rapidly improve.<xref ref-type="bibr" rid="article-27034.r36">[36]</xref></p>
      </sec>
      <sec id="article-27034.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Patients with pernicious anemia are at an increased risk of gastric cancer. An international meta-analysis of over 22,000 patients with pernicious anemia found a pooled gastric cancer incidence of 0.27% per person-year. The same study showed a pooled gastric cancer recurrence rate of 6.8.<xref ref-type="bibr" rid="article-27034.r37">[37]</xref></p>
        <p>A large United States population study based on a Surveillance, Epidemiology, and End Results (SEER) Medicare database found an increased risk of 10 cancer types. The authors state, &#x0201c;The most striking of our findings was an 11-fold increase in the risk of gastric carcinoid tumors for both men and women with pernicious anemia, a risk that was higher among cases occurring 6 or more years after the pernicious anemia report/diagnosis.&#x0201d; They&#x000a0;also point out these are uncommon cancers with low absolute risk: &#x0201c;Of the 17,076 cancers in our study among people with pernicious anemia, just 83 (0.5%) were gastric carcinoid tumors.&#x0201d;<xref ref-type="bibr" rid="article-27034.r38">[38]</xref>&#x000a0;</p>
        <p>
<bold>Management Guidelines</bold>
</p>
        <p>British Society of Gastroenterology (2019): "We suggest that a baseline endoscopy with biopsies should be considered in individuals aged &#x02265;50 years, with laboratory evidence of pernicious anemia, defined by vitamin B12 deficiency and either positive gastric parietal cell or intrinsic factor antibodies. As gastric adenocarcinoma affects the corpus in pernicious anemia, biopsies should be taken from the greater and lesser curves (evidence level: low quality; grade of recommendation: weak; level of agreement: 93%)."<xref ref-type="bibr" rid="article-27034.r39">[39]</xref></p>
        <p>European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) (2019): "Patients with autoimmune gastritis (includes those with pernicious anemia) may benefit from endoscopic follow-up every 3 to 5 years. Low-quality evidence, weak recommendation (82% agree [76% strongly or moderately agree])."<xref ref-type="bibr" rid="article-27034.r40">[40]</xref></p>
        <p>American Gastroenterological Association (2021): "Providers should recognize pernicious anemia as a late-stage manifestation of autoimmune gastritis that is characterized by vitamin B-12 deficiency and macrocytic anemia. Patients with a new diagnosis of pernicious anemia who have not had a recent endoscopy should undergo endoscopy with topographical biopsies to confirm corpus-predominant atrophic gastritis for risk stratification and to rule out prevalent gastric neoplasia, including neuroendocrine tumors."<xref ref-type="bibr" rid="article-27034.r3">[3]</xref></p>
      </sec>
      <sec id="article-27034.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education is primarily focused on treatment; however, patients should also be advised about their increased risk of cancer, particularly gastric, and pernicious anemia&#x02019;s association with other autoimmune disorders. Clinicians must recognize proper adherence to lifelong treatment and monitoring requires consideration of the patient&#x02019;s preferred route of vitamin B12 supplementation. Patients choosing oral therapy may confuse it with optional self-supplementation, and those who choose IM injections may require education regarding self-administration. Furthermore, patients may inadvertently discontinue treatment when their symptoms improve or resolve. Ongoing patient education improves the chances of patients adhering to the necessary lifelong treatment and monitoring.&#x000a0;They must also be educated on the signs and symptoms of&#x000a0;other autoimmune disorders and gastric malignancies to&#x000a0;improve their chances of earlier diagnosis and treatment.&#x000a0;</p>
      </sec>
      <sec id="article-27034.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with pernicious anemia can present in one or more clinical settings due to this insidious condition's wide array of potential manifestations. They may be seen by providers in the area(s) of nutrition, primary care, hematology, gastroenterology, neurology, psychiatry, rheumatology, and endocrinology, to name a few. Making the correct diagnosis will include laboratory scientists and may also include pathologists. Once diagnosed, the patient's care may involve a medical assistant, nurse, physician assistant, nurse practitioner, physician, and pharmacist.</p>
        <p>Patients require a lifelong coordinated effort by an interprofessional team to enhance healthcare team outcomes. For example, a hematologist prescribing B12 supplementation and ordering bloodwork, a medical assistant administering IM B12 injections, a gastroenterologist providing surveillance for gastric cancer, an endocrinologist treating diabetes mellitus, and a pharmacist reconciling medications.[Level 5]</p>
      </sec>
      <sec id="article-27034.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27034&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27034">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/pernicious-anemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27034">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27034/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27034">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27034.s15">
        <fig id="article-27034.image.f1" position="float" orientation="portrait">
          <caption>
            <p>The peripheral smear shows characteristic hypersegmented neutrophil and macro ovalocytes which is found in megaloblastic anemia Atif Irfan Khan MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10427" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27034.s16">
        <title>References</title>
        <ref id="article-27034.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Htut</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Thein</surname>
                <given-names>KZ</given-names>
              </name>
              <name>
                <surname>Oo</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Pernicious anemia: Pathophysiology and diagnostic difficulties.</article-title>
            <source>J Evid Based Med</source>
            <year>2021</year>
            <month>May</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-169</page-range>
            <pub-id pub-id-type="pmid">34015185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenti</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Rugge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lahner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miceli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Toh</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Genta</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>De Block</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hershko</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Di Sabatino</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune gastritis.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2020</year>
            <month>Jul</month>
            <day>09</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <pub-id pub-id-type="pmid">32647173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Piazuelo</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Kuipers</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review.</article-title>
            <source>Gastroenterology</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>161</volume>
            <issue>4</issue>
            <fpage>1325</fpage>
            <page-range>1325-1332.e7</page-range>
            <pub-id pub-id-type="pmid">34454714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rustgi</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Bijlani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management.</article-title>
            <source>Therap Adv Gastroenterol</source>
            <year>2021</year>
            <volume>14</volume>
            <fpage>17562848211038771</fpage>
            <pub-id pub-id-type="pmid">34484423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahaly</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Type 1 diabetes associated autoimmunity.</article-title>
            <source>Autoimmun Rev</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>644</fpage>
            <page-range>644-8</page-range>
            <pub-id pub-id-type="pmid">26903475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ness-Abramof</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nabriski</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Braverman</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Shilo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Reshef</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Shenkman</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and evaluation of B12 deficiency in patients with autoimmune thyroid disease.</article-title>
            <source>Am J Med Sci</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>332</volume>
            <issue>3</issue>
            <fpage>119</fpage>
            <page-range>119-22</page-range>
            <pub-id pub-id-type="pmid">16969140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dahir</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Comorbidities in vitiligo: comprehensive review.</article-title>
            <source>Int J Dermatol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>57</volume>
            <issue>10</issue>
            <fpage>1157</fpage>
            <page-range>1157-1164</page-range>
            <pub-id pub-id-type="pmid">29808541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laisk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lepamets</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abner</surname>
                <given-names>E</given-names>
              </name>
              <collab>Estonian Biobank Research Team</collab>
              <name>
                <surname>M&#x000e4;gi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Genome-wide association study identifies five risk loci for pernicious anemia.</article-title>
            <source>Nat Commun</source>
            <year>2021</year>
            <month>Jun</month>
            <day>18</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>3761</fpage>
            <pub-id pub-id-type="pmid">34145262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carabotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Annibale</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lahner</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Common Pitfalls in the Management of Patients with Micronutrient Deficiency: Keep in Mind the Stomach.</article-title>
            <source>Nutrients</source>
            <year>2021</year>
            <month>Jan</month>
            <day>13</day>
            <volume>13</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">33450823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stabler</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Vitamin B12 deficiency as a worldwide problem.</article-title>
            <source>Annu Rev Nutr</source>
            <year>2004</year>
            <volume>24</volume>
            <fpage>299</fpage>
            <page-range>299-326</page-range>
            <pub-id pub-id-type="pmid">15189123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stabler</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice. Vitamin B12 deficiency.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Jan</month>
            <day>10</day>
            <volume>368</volume>
            <issue>2</issue>
            <fpage>149</fpage>
            <page-range>149-60</page-range>
            <pub-id pub-id-type="pmid">23301732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maktouf</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bchir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Louzir</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mdhaffer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elloumi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ben Abid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Meddeb</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Makni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Laatiri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soussi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hafsia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dellagi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Megaloblastic anemia in North Africa.</article-title>
            <source>Haematologica</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>91</volume>
            <issue>7</issue>
            <fpage>990</fpage>
            <page-range>990-1</page-range>
            <pub-id pub-id-type="pmid">16757418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Vitamin B<sub>12</sub> deficiency from the perspective of a practicing hematologist.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>May</month>
            <day>11</day>
            <volume>129</volume>
            <issue>19</issue>
            <fpage>2603</fpage>
            <page-range>2603-2611</page-range>
            <pub-id pub-id-type="pmid">28360040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fedosov</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Fedosova</surname>
                <given-names>NU</given-names>
              </name>
              <name>
                <surname>Kr&#x000e4;utler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nex&#x000f8;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of discrimination between cobalamins and their natural analogues during their binding to the specific B12-transporting proteins.</article-title>
            <source>Biochemistry</source>
            <year>2007</year>
            <month>May</month>
            <day>29</day>
            <volume>46</volume>
            <issue>21</issue>
            <fpage>6446</fpage>
            <page-range>6446-58</page-range>
            <pub-id pub-id-type="pmid">17487979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nielsen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Nex&#x000f8;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moestrup</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Vitamin B12 transport from food to the body's cells--a sophisticated, multistep pathway.</article-title>
            <source>Nat Rev Gastroenterol Hepatol</source>
            <year>2012</year>
            <month>May</month>
            <day>01</day>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>345</fpage>
            <page-range>345-54</page-range>
            <pub-id pub-id-type="pmid">22547309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Bj&#x000f8;rke-Monsen</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Brito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gu&#x000e9;ant</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Molloy</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Nexo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stabler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Toh</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Ueland</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Yajnik</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Vitamin B<sub>12</sub> deficiency.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2017</year>
            <month>Jun</month>
            <day>29</day>
            <volume>3</volume>
            <fpage>17040</fpage>
            <pub-id pub-id-type="pmid">28660890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolffenbuttel</surname>
                <given-names>BHR</given-names>
              </name>
              <name>
                <surname>Wouters</surname>
                <given-names>HJCM</given-names>
              </name>
              <name>
                <surname>Heiner-Fokkema</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>van der Klauw</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>The Many Faces of Cobalamin (Vitamin B<sub>12</sub>) Deficiency.</article-title>
            <source>Mayo Clin Proc Innov Qual Outcomes</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>200</fpage>
            <page-range>200-214</page-range>
            <pub-id pub-id-type="pmid">31193945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cahill</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Roffman</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lamon-Fava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fava</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mischoulon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>S-Adenosyl Methionine and Transmethylation Pathways in Neuropsychiatric Diseases Throughout Life.</article-title>
            <source>Neurotherapeutics</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>156</fpage>
            <page-range>156-175</page-range>
            <pub-id pub-id-type="pmid">29340929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>N-homocysteinylation induces different structural and functional consequences on acidic and basic proteins.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>12</issue>
            <fpage>e116386</fpage>
            <pub-id pub-id-type="pmid">25551634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Refsum</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Homocysteine, B Vitamins, and Cognitive Impairment.</article-title>
            <source>Annu Rev Nutr</source>
            <year>2016</year>
            <month>Jul</month>
            <day>17</day>
            <volume>36</volume>
            <fpage>211</fpage>
            <page-range>211-39</page-range>
            <pub-id pub-id-type="pmid">27431367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carmel</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>How I treat cobalamin (vitamin B12) deficiency.</article-title>
            <source>Blood</source>
            <year>2008</year>
            <month>Sep</month>
            <day>15</day>
            <volume>112</volume>
            <issue>6</issue>
            <fpage>2214</fpage>
            <page-range>2214-21</page-range>
            <pub-id pub-id-type="pmid">18606874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohamed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pernicious anaemia.</article-title>
            <source>BMJ</source>
            <year>2020</year>
            <month>Apr</month>
            <day>24</day>
            <volume>369</volume>
            <fpage>m1319</fpage>
            <pub-id pub-id-type="pmid">32332011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bizzaro</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Antico</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and classification of pernicious anemia.</article-title>
            <source>Autoimmun Rev</source>
            <year>2014</year>
            <season>Apr-May</season>
            <volume>13</volume>
            <issue>4-5</issue>
            <fpage>565</fpage>
            <page-range>565-8</page-range>
            <pub-id pub-id-type="pmid">24424200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vasconcelos</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Poehm</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>McCarter</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Quezado</surname>
                <given-names>ZM</given-names>
              </name>
            </person-group>
            <article-title>Potential outcome factors in subacute combined degeneration: review of observational studies.</article-title>
            <source>J Gen Intern Med</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>10</issue>
            <fpage>1063</fpage>
            <page-range>1063-8</page-range>
            <pub-id pub-id-type="pmid">16970556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mrabet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ellouze</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ellini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mrad</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>[Neuropsychiatric manifestations ushering pernicious anemia].</article-title>
            <source>Encephale</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>550</fpage>
            <page-range>550-5</page-range>
            <pub-id pub-id-type="pmid">26345354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devalia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Molloy</surname>
                <given-names>AM</given-names>
              </name>
              <collab>British Committee for Standards in Haematology</collab>
            </person-group>
            <article-title>Guidelines for the diagnosis and treatment of cobalamin and folate disorders.</article-title>
            <source>Br J Haematol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>166</volume>
            <issue>4</issue>
            <fpage>496</fpage>
            <page-range>496-513</page-range>
            <pub-id pub-id-type="pmid">24942828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lahner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Annibale</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pernicious anemia: new insights from a gastroenterological point of view.</article-title>
            <source>World J Gastroenterol</source>
            <year>2009</year>
            <month>Nov</month>
            <day>07</day>
            <volume>15</volume>
            <issue>41</issue>
            <fpage>5121</fpage>
            <page-range>5121-8</page-range>
            <pub-id pub-id-type="pmid">19891010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Annibale</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lahner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fave</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of pernicious anemia.</article-title>
            <source>Curr Gastroenterol Rep</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>518</fpage>
            <page-range>518-24</page-range>
            <pub-id pub-id-type="pmid">21947876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andres</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Serraj</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Optimal management of pernicious anemia.</article-title>
            <source>J Blood Med</source>
            <year>2012</year>
            <volume>3</volume>
            <fpage>97</fpage>
            <page-range>97-103</page-range>
            <pub-id pub-id-type="pmid">23028239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Habeych</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Silva-Zolezzi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Galaffu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Methods to assess vitamin B12 bioavailability and technologies to enhance its absorption.</article-title>
            <source>Nutr Rev</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>76</volume>
            <issue>10</issue>
            <fpage>778</fpage>
            <page-range>778-792</page-range>
            <pub-id pub-id-type="pmid">29931214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hvas</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Morkbak</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Nexo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Plasma holotranscobalamin compared with plasma cobalamins for assessment of vitamin B12 absorption; optimisation of a non-radioactive vitamin B12 absorption test (CobaSorb).</article-title>
            <source>Clin Chim Acta</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>376</volume>
            <issue>1-2</issue>
            <fpage>150</fpage>
            <page-range>150-4</page-range>
            <pub-id pub-id-type="pmid">16989796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hvas</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Morkbak</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Hardlei</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Nexo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The vitamin B12 absorption test, CobaSorb, identifies patients not requiring vitamin B12 injection therapy.</article-title>
            <source>Scand J Clin Lab Invest</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>432</fpage>
            <page-range>432-8</page-range>
            <pub-id pub-id-type="pmid">21623649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lahner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Severi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Encabo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shums</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Vannella</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Delle Fave</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Annibale</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>104</volume>
            <issue>8</issue>
            <fpage>2071</fpage>
            <page-range>2071-9</page-range>
            <pub-id pub-id-type="pmid">19491828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cattan</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pernicious anemia: what are the actual diagnosis criteria?</article-title>
            <source>World J Gastroenterol</source>
            <year>2011</year>
            <month>Jan</month>
            <day>28</day>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>543</fpage>
            <page-range>543-4</page-range>
            <pub-id pub-id-type="pmid">21274387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>CQ</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Oral Vitamin B12 Replacement for the Treatment of Pernicious Anemia.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2016</year>
            <volume>3</volume>
            <fpage>38</fpage>
            <pub-id pub-id-type="pmid">27602354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Neurologic aspects of cobalamin (B12) deficiency.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2014</year>
            <volume>120</volume>
            <fpage>915</fpage>
            <page-range>915-26</page-range>
            <pub-id pub-id-type="pmid">24365360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vannella</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lahner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Osborn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Annibale</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Systematic review: gastric cancer incidence in pernicious anaemia.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>375</fpage>
            <page-range>375-82</page-range>
            <pub-id pub-id-type="pmid">23216458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dawsey</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Engels</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Ricker</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Etemadi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Abnet</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>ND</given-names>
              </name>
            </person-group>
            <article-title>Cancer Risk After Pernicious Anemia in the US Elderly Population.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>13</issue>
            <fpage>2282</fpage>
            <page-range>2282-9.e1-4</page-range>
            <pub-id pub-id-type="pmid">26079040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Banks</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gotoda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Coda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>di Pietro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Uedo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bhandari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pritchard</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Kuipers</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Rodriguez-Justo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Novelli</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Ragunath</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dinis-Ribeiro</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma.</article-title>
            <source>Gut</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>68</volume>
            <issue>9</issue>
            <fpage>1545</fpage>
            <page-range>1545-1575</page-range>
            <pub-id pub-id-type="pmid">31278206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27034.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pimentel-Nunes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lib&#x000e2;nio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marcos-Pinto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Areia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leja</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Garrido</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kikuste</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Megraud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Matysiak-Budnik</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Annibale</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dumonceau</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Barros</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fl&#x000e9;jou</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Carneiro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van Hooft</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kuipers</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Dinis-Ribeiro</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019.</article-title>
            <source>Endoscopy</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>365</fpage>
            <page-range>365-388</page-range>
            <pub-id pub-id-type="pmid">30841008</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
